$LQDA News

Last published 3d ago

3d agoLQDALiquidia Corporation to Present at 2026 Jefferies Global Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer,...
3d agoLQDALiquidia Corp - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
3d agoLQDALiquidia Corporation Reports Third Quarter 2026 Financial ResultsGlobeNewswireMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to dis ...
3d agoLQDALiquidia Corporation Reports Third Quarter 2026 Financial ResultsGlobeNewswireYUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026October 2026 total patient shipments reached their highest monthly level
1w agoLQDALiquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswireMORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
1mo agoLQDA UTHRLiquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHGlobeNewswireFully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)Liquidia to pay net $380.7 million in multiple installments
1mo agoLQDALIQUIDIA CORPORATION INVESTIGATION: LQDA Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewswireNEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). The
2mo agoLQDAFDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic SclerosisGlobeNewswireFast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patientsNo therapy
2mo agoLQDALiquidia to Present Posters at the European Respiratory Society (ERS) 2026 CongressGlobeNewswireMORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory
2mo agoLQDALiquidia Corporation to Participate in Wells Fargo Annual Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business
3mo agoLQDALiquidia Second Quarter 2026 Financial Results and Corporate Update Call - LIQUIDIA CORPEarnings Call TranscriptsGood morning, and welcome to the Liquidia Corporation second quarter 2026 Financial Results and Corporate Update conference call. My name is Daniel, and I will be your operator today. All participants are currently in li
3mo agoLQDALiquidia Corporation Reports Second Quarter 2026 Financial ResultsGlobeNewswireYUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026Approximately 5,900 unique patient prescriptions and more
3mo agoLQDALiquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireMORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
5mo agoLQDALiquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific SessionsGlobeNewswireMORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
5mo agoLQDALiquidia Corporation Announces Inclusion in the S&P SmallCap 600® IndexGlobeNewswireMORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
5mo agoLQDAJeffries Global Healthcare Conference in New York - Liquidia CorporationEarnings Call TranscriptsOkay, awesome. Let's get started and like, yeah, okay, let's get started. Thank you, everyone, for attending the Jeffries New York Healthcare Conference. I am Amy Lee. I'm a biotech analyst at Jeffries, and I have the pl
5mo agoLQDALiquidia Corporation to Present at 2026 Jefferies Global Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial
6mo agoLQDA2026 GLOBAL HEALTHCARE CONFERENCE - LIQUIDIA CORPEarnings Call TranscriptsAll right, everybody, we're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerber. I cover pharma and biotech at B of B. I'm pleased to be introducing
6mo agoLQDALiquidia First Quarter 2026 Financial Results and Corporate Update Call - LiquidiaEarnings Call TranscriptsGood morning and welcome to Liquidia Corporation First Quarter 2026 Financial Results and Corporate Update Conference Call. My name is Jonathan and I will be your operator today. All participants are currently in a liste
6mo agoLQDALiquidia Corporation Reports First Quarter 2026 Financial ResultsGlobeNewswireYUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between
6mo agoLQDALiquidia Corporation to Participate in Upcoming Investor ConferencesGlobeNewswireMORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
6mo agoLQDALiquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026GlobeNewswireMORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
7mo agoLQDALiquidia Corporation to Participate in Upcoming Investor ConferencesGlobeNewswireMORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and
8mo agoLQDALiquidia Full Year 2025 Financial Results and Corporate Update Call - LiquidiaEarnings Call TranscriptsGood morning, and welcome to the Liquidia Corporation Full Year 2025 Financial Results and Corporate Update Conference Call. My name is Josh, and I will be your operator today. All participants are currently in listen-on
8mo agoLQDALiquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireAchieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in
8mo agoLQDALiquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026GlobeNewswireMORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today
9mo agoLQDALiquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual CongressGlobeNewswireMORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today
10mo agoLQDALiquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate UpdateGlobeNewswireEstimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June
10mo agoLQDALiquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference
1y agoLQDALiquidia Third Quarter 2025 Financial Results and Corporate Update Call - LiquidiaEarnings Call TranscriptsGood morning and welcome to the Liquidia Corporation third quarter 2025 financial results and corporate update conference call. My name is Carmen and I will be your operator today. All participants are current in analysi
1y agoLQDALiquidia Corporation to Present at Upcoming Healthcare Investment ConferencesGlobeNewswireMORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today
1y agoLQDALiquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireRecorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient
1y agoLQDALiquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025GlobeNewswireMORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that
1y agoLQDALiquidia Corporation to Host R&D Day in New York City on October 28, 2025GlobeNewswireMORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that
1y agoLQDALiquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual MeetingGlobeNewswireMORRISVILLE, N.C., Sept.
1y agoLQDALiquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) SymposiumGlobeNewswireMORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that
1y agoLQDALiquidia Corporation to Present at the 2025 Wells Fargo Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that members of the company's executive leadership team will be providing an update on the company's business
1y agoLQDALiquidia Corporation (LQDA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoLQDALiquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireYUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and
1y agoLQDALiquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireMORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that
1y agoLQDALiquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILDGlobeNewswireYUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics' request for preliminary injunction and a temporary restraining order,
1y agoLQDALiquidia Corporation to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer
1y agoLQDAU.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)GlobeNewswireFDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low
1y agoLQDALiquidia Corporation Provides Update on Litigation Filed by United TherapeuticsGlobeNewswireNew litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR's ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent
1y agoLQDALiquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireAwaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in
1y agoLQDALiquidia Corporation to Present at BofA Securities 2025 Health Care ConferenceGlobeNewswireMORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that
1y agoLQDADistrict Court Dismisses Dispute Filed by United Therapeutics Against LiquidiaGlobeNewswireCourt will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025
1y agoLQDALiquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025GlobeNewswireMORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that
1y agoLQDAUPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced
1y agoLQDALiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that